StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Travere Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 98.6%. For fiscal 2026 it was 97.9%, against 96.7% the year before. The highest annual figure on record is 98.0% in fiscal 2015.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2026Dec 31, 202597.9%+1.2
FY2025Dec 31, 202496.7%+4.6
FY2024Dec 31, 202392.1%−3.8
FY2023Dec 31, 202296.0%−1.1
FY2022Dec 31, 202197.1%+0.2
FY2021Dec 31, 202096.9%−0.1
FY2020Dec 31, 201997.0%+0.4
FY2019Dec 31, 201896.6%−1.0
FY2018Dec 31, 201797.7%+1.1
FY2017Dec 31, 201696.6%−1.2
FY2016Dec 31, 201597.8%−0.2
FY2015Dec 31, 201498.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2027Jun 30, 202698.7%+0.0
Q1 FY2027Mar 31, 202698.5%+4.2
Q4 FY2026Dec 31, 202598.0%+1.4
Q3 FY2026Sep 30, 202599.0%+1.6
Q2 FY2026Jun 30, 202598.7%+2.5
Q1 FY2026Mar 31, 202594.3%−2.1
Q4 FY2025Dec 31, 202496.6%+6.7
Q3 FY2025Sep 30, 202497.4%+0.9
Q2 FY2025Jun 30, 202496.2%+0.7
Q1 FY2025Mar 31, 202496.4%+9.8
Q4 FY2024Dec 31, 202389.9%−7.2
Q3 FY2024Sep 30, 202396.5%+0.5
Q2 FY2024Jun 30, 202395.5%+2.7
Q1 FY2024Mar 31, 202386.6%−4.3
Q4 FY2023Dec 31, 202297.0%+0.4
Q3 FY2023Sep 30, 202296.0%−1.6
Q2 FY2023Jun 30, 202292.8%−4.1
Q1 FY2023Mar 31, 202290.9%−5.7
Q4 FY2022Dec 31, 202196.7%+0.8
Q3 FY2022Sep 30, 202197.7%−0.0
Q2 FY2022Jun 30, 202197.0%+0.1
Q1 FY2022Mar 31, 202196.5%−0.6
Q4 FY2021Dec 31, 202095.9%−0.4
Q3 FY2021Sep 30, 202097.7%+1.1
Q2 FY2021Jun 30, 202096.9%−0.9
Q1 FY2021Mar 31, 202097.1%−0.3
Q4 FY2020Dec 31, 201996.3%−0.0
Q3 FY2020Sep 30, 201996.6%−0.6
Q2 FY2020Jun 30, 201997.8%+0.7
Q1 FY2020Mar 31, 201997.4%+1.6
Q4 FY2019Dec 31, 201896.3%−0.9
Q3 FY2019Sep 30, 201897.2%−0.5
Q2 FY2019Jun 30, 201897.2%−0.8
Q1 FY2019Mar 31, 201895.8%−2.1
Q4 FY2018Dec 31, 201797.2%+0.4
Q3 FY2018Sep 30, 201797.7%+2.3
Q2 FY2018Jun 30, 201797.9%–
Q1 FY2018Mar 31, 201797.9%–
Q4 FY2017Dec 31, 201696.8%–
Q3 FY2017Sep 30, 201695.4%–

More Travere Therapeutics figures

See a number that looks wrong?